Association between antidiabetic drugs and cancer risk in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis

Figure 1 Literature search and screening flowchart.

Figure 2 Results of the effects of different types of antidiabetic drugs on any cancer, lung cancer, bronchial cancer, and thyroid cancer. A and B: Any cancer; C and D: Lung cancer; E and F: Bronchial cancer; G and H: Thyroid cancer. DPP-4i: Dipeptidyl peptidase-4 inhibitors; SGLT-2i: Sodium-glucose cotransporter 2 inhibitors; GLP-1RA: Glucagon-like peptide-1 receptor agonists; CI: Confidence interval.

Figure 3 Results of the effects of different types of antidiabetic drugs on gastric cancer, pancreatic cancer, rectal cancer, and colon cancer. A and B: Gastric cancer; C and D: Pancreatic cancer; E and F: Rectal cancer; G and H: Colon cancer. DPP-4i: Dipeptidyl peptidase-4 inhibitors; SGLT-2i: Sodium-glucose cotransporter 2 inhibitors; GLP-1RA: Glucagon-like peptide-1 receptor agonists; CI: Confidence interval.

Figure 4 Results of the effects of different types of antidiabetic drugs on bladder cancer, prostate cancer, uterine cancer, and breast cancer. A and B: Bladder cancer; C and D: Prostate cancer; E and F: Uterine cancer; G and H: Breast cancer. DPP-4i: Dipeptidyl peptidase-4 inhibitors; SGLT-2i: Sodium-glucose cotransporter 2 inhibitors; GLP-1RA: Glucagon-like peptide-1 receptor agonists; CI: Confidence interval.

Figure 5 Results of the effects of different types of antidiabetic drugs on hepatocellular cancer, renal cancer, and hematologic cancer. A and B: Hepatocellular cancer; C and D: Renal cancer; E and F: Hematologic cancer. DPP-4i: Dipeptidyl peptidase-4 inhibitors; SGLT-2i: Sodium-glucose cotransporter 2 inhibitors; GLP-1RA: Glucagon-like peptide-1 receptor agonists; CI: Confidence interval.